Merck & Co., Inc. (NYSE: MRK) reported Q2 EPS of $0.95, in-line with the analyst estimate of $0.95. Revenue for the quarter came in at $12.2 billion versus the consensus estimate of $11.78 million.

To cut workforce by added 12-13% by end of 2015.

Raises the lower end of its FY11 EPS range to $3.68-$3.76, the Street is currently looking for EPS of $3.74.

Earnings Guidance Hot Earnings Hot Guidance